Literature DB >> 29404788

Surgical Treatment of Valvular Heart Disease: Overview of Mechanical and Tissue Prostheses, Advantages, Disadvantages, and Implications for Clinical Use.

Amy G Fiedler1, George Tolis2.   

Abstract

Valvular heart disease (VHD) affects a large number of patients annually. From a surgical standpoint, there are two primary options for valve replacement: mechanical or bioprosthetic. While there are clear advantages and disadvantages to either option, and recent literature does challenge some of the prior dictums of valve choice, a handful of absolutes remain true. Mechanical valves provide superior durability and freedom from re-operation when compared to their bioprosthetic counterparts, at the expense of bleeding or thrombotic complications associated with the need for lifelong oral anticoagulation. Unless a clear contraindication to oral anticoagulation exists, we recommend implanting mechanical valves for patients less than 60 years old and those who are older than 65 but maintained on anticoagulation for reasons other than their valvular disease. Bioprosthetic valves should be placed in patients who are greater than 65 years old or those patients who have a postoperative life expectancy of less than 10 years. Valve choice in patients between the ages of 60 to 70 is not dictated by guidelines and is less clear, with patient preference playing a larger role than their age range.

Entities:  

Keywords:  Aortic valve replacement; Bioprosthetic heart valves; Mechanical heart valves; Mitral valve replacement; Valvular heart disease

Year:  2018        PMID: 29404788     DOI: 10.1007/s11936-018-0601-7

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  41 in total

1.  Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study).

Authors:  E C Jones; R B Devereux; M J Roman; J E Liu; D Fishman; E T Lee; T K Welty; R R Fabsitz; B V Howard
Journal:  Am J Cardiol       Date:  2001-02-01       Impact factor: 2.778

2.  Early Trifecta valve failure: Report of a cluster of cases from a tertiary care referral center.

Authors:  Ankur Kalra; Hasan Rehman; Mahesh Ramchandani; Colin M Barker; Gerald M Lawrie; Ross M Reul; Michael J Reardon; Neal S Kleiman
Journal:  J Thorac Cardiovasc Surg       Date:  2017-05-22       Impact factor: 5.209

3.  Aortic valve replacement with the Mitroflow pericardial bioprosthesis: durability results up to 21 years.

Authors:  Charles A Yankah; Miralem Pasic; Michele Musci; Julia Stein; Christine Detschades; Henryk Siniawski; Roland Hetzer
Journal:  J Thorac Cardiovasc Surg       Date:  2008-07-14       Impact factor: 5.209

Review 4.  Prosthetic Heart Valve Thrombosis.

Authors:  George D Dangas; Jeffrey I Weitz; Gennaro Giustino; Raj Makkar; Roxana Mehran
Journal:  J Am Coll Cardiol       Date:  2016-12-20       Impact factor: 24.094

5.  Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old.

Authors:  Tsuyoshi Kaneko; Sary Aranki; Quratulain Javed; Siobhan McGurk; Prem Shekar; Michael Davidson; Lawrence Cohn
Journal:  J Thorac Cardiovasc Surg       Date:  2013-09-27       Impact factor: 5.209

Review 6.  Choice of prosthetic heart valve in adults an update.

Authors:  Shahbudin H Rahimtoola
Journal:  J Am Coll Cardiol       Date:  2010-06-01       Impact factor: 24.094

7.  Durability of bioprosthetic cardiac valves.

Authors:  Grischa Hoffmann; Georg Lutter; Jochen Cremer
Journal:  Dtsch Arztebl Int       Date:  2008-02-22       Impact factor: 5.594

8.  Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial.

Authors:  John Puskas; Marc Gerdisch; Dennis Nichols; Reed Quinn; Charles Anderson; Birger Rhenman; Lilibeth Fermin; Michael McGrath; Bobby Kong; Chad Hughes; Gulshan Sethi; Michael Wait; Tomas Martin; Allen Graeve
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-12       Impact factor: 5.209

9.  Aortic allograft valve reoperation: surgical challenges and patient risks.

Authors:  Edward R Nowicki; Gösta B Pettersson; Nicholas G Smedira; Eric E Roselli; Eugene H Blackstone; Bruce W Lytle
Journal:  Ann Thorac Surg       Date:  2008-09       Impact factor: 4.330

10.  St. Jude Medical Trifecta aortic valve: results from a prospective regional multicentre registry.

Authors:  Giovanni Mariscalco; Silvia Mariani; Samuele Bichi; Andrea Biondi; Andrea Blasio; Paolo Borsani; Fabrizio Corti; Benedetta De Chiara; Riccardo Gherli; Cristian Leva; Claudio Francesco Russo; Giordano Tasca; Paolo Vanelli; Ottavio Alfieri; Carlo Antona; Germano Di Credico; Giampiero Esposito; Amando Gamba; Luigi Martinelli; Lorenzo Menicanti; Giovanni Paolini; Cesare Beghi
Journal:  J Cardiothorac Surg       Date:  2015-11-20       Impact factor: 1.637

View more
  6 in total

Review 1.  Tissue Valve Degeneration and Mechanical Valve Failure.

Authors:  Andrew C W Baldwin; George Tolis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-06-14

Review 2.  Natural Polymers in Heart Valve Tissue Engineering: Strategies, Advances and Challenges.

Authors:  Diana Elena Ciolacu; Raluca Nicu; Florin Ciolacu
Journal:  Biomedicines       Date:  2022-05-08

3.  Hydrodynamic Noise of Pulsating Jets through Bileaflet Mechanical Mitral Valve.

Authors:  Vladimir Voskoboinick; Oleksandr Voskoboinyk; Oleg Chertov; Andrey Voskoboinick; Lidiia Tereshchenko
Journal:  Biomed Res Int       Date:  2020-05-30       Impact factor: 3.411

4.  After 50 Years of Heart Transplants: What Does the Next 50 Years Hold for Cardiovascular Medicine? A Perspective From the International Society for Applied Cardiovascular Biology.

Authors:  Joshua D Hutcheson; Craig J Goergen; Frederick J Schoen; Masanori Aikawa; Peter Zilla; Elena Aikawa; Glenn R Gaudette
Journal:  Front Cardiovasc Med       Date:  2019-02-14

Review 5.  The Structural Complexity and Animal Tissue Distribution of N-Glycolylneuraminic Acid (Neu5Gc)-Terminated Glycans. Implications for Their Immunogenicity in Clinical Xenografting.

Authors:  Michael E Breimer; Jan Holgersson
Journal:  Front Mol Biosci       Date:  2019-07-19

6.  Hemocompatibile Thin Films Assessed under Blood Flow Shear Forces.

Authors:  Roman Major; Grażyna Wilczek; Justyna Więcek; Maciej Gawlikowski; Hanna Plutecka; Katarzyna Kasperkiewicz; Marcin Kot; Małgorzata Pomorska; Roman Ostrowski; Magdalena Kopernik
Journal:  Molecules       Date:  2022-09-04       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.